Get the Stockscreener App
0.00
100.00%
-4.26
Checkpoint Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
See More
Previous Close:
$4.26
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$364.61M
Revenue:
$103.00K
Net Income/Loss:
$-42.47M
P/E Ratio:
0.00
EPS:
-1.9
Net Cash Flow:
$-34.30M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$4.50
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Name
Checkpoint Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
95 SAWYER ROAD, WALTHAM, NY
Compare CKPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CKPT
Checkpoint Therapeutics Inc
|
0.00 | 364.61M | 103.00K | -42.47M | -34.30M | -1.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.27 | 114.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.67 | 55.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.56 | 39.64B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
557.00 | 35.64B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
265.10 | 28.55B | 3.81B | -644.79M | -669.77M | -6.24 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Jul-14-22 | Resumed | B. Riley Securities | Buy |
| Jun-09-21 | Initiated | B. Riley Securities | Buy |
| Jan-20-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-19 | Initiated | Lake Street | Buy |
| Dec-08-17 | Initiated | H.C. Wainwright | Buy |
View All
Checkpoint Therapeutics Inc Stock (CKPT) Latest News
Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Shares Bought by Bank of America Corp DE - Defense World
54,186 Shares in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Acquired by Millennium Management LLC - Defense World
Two Sigma Investments LP Grows Stock Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Squarepoint Ops LLC Purchases Shares of 71,938 Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Wealth Enhancement Advisory Services LLC Has $1.36 Million Stock Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Northern Trust Corp Purchases 10,232 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics, Inc.(NasdaqCM: CKPT) dropped from S&P TMI Index - marketscreener.com
Checkpoint Therapeutics Completes Merger with Sun Pharma Subsidiary - MSN
Sun Pharma concludes acquisition of Checkpoint Therapeutics - Medical Dialogues
Sun Pharma Finalizes $416M Deal for Checkpoint Therapeutics, Inc. (CKPT) - Insider Monkey
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpo - GuruFocus
Checkpoint Therapeutics finalizes acquisition by Sun Pharma - Investing.com Nigeria
Sun Pharma Completes its Acquisition of Checkpoint Therapeutics - citybiz
Sun Pharma completes its acquisition of Checkpoint Therapeutics - Moneycontrol
Fortress Biotech Announces Sale of Subsidiary Checkpoint Therapeutics - citybiz
Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics - marketscreener.com
Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit - marketscreener.com
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - The Manila Times
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics | FBIO Stock News - GuruFocus
Fortress Biotech, Inc. Announces Acquisition of Checkpoint Therapeutics by Sun Pharmaceutical Industries Limited - Nasdaq
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics - Benzinga
Fortress Biotech Cashes In: $28M Upfront Plus Royalties in Strategic Checkpoint Sale to Sun Pharma - Stock Titan
Checkpoint Therapeutics finalizes acquisition by Sun Pharma By Investing.com - Investing.com South Africa
Checkpoint Therapeutics shareholders approve Sun Pharma merger By Investing.com - Investing.com India
Checkpoint Therapeutics shareholders approve Sun Pharma merger - Investing.com
Checkpoint Therapeutics Approves Merger with Sun Pharma - TipRanks
D. E. Shaw & Co. Inc. Has $95,000 Position in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics, Inc. (CKPT) Stock Analysis: Is There More Room to Grow Beyond Its 2.44% Potential Upside? - DirectorsTalk Interviews
Checkpoint Pharma Sued Over Controversial $355M Merger - USA Herald
Checkpoint Investor Sues for Info on Sale From Fortress to Sun - Bloomberg Law News
Checkpoint Therapeutics Reports Q1 2025 Financials and Updates - TipRanks
Checkpoint Therapeutics Announces Merger Progress By Investing.com - Investing.com Canada
Checkpoint Therapeutics Announces Merger Progress - Investing.com
Checkpoint Therapeutics Merger Awaits Stockholder Vote - TipRanks
Cancer Drug Co. Beats Investor Suit Over FDA Rejection - Law360
Checkpoint Therapeutics Beats Investor Suit Over FDA Assent (1) - Bloomberg Law News
Balyasny Asset Management L.P. Buys New Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Stifel Financial Corp Acquires New Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech Earnings: Triple Win with $28M Checkpoint Deal, FDA Fast-Track, and Rosacea Drug Launch - Stock Titan
Lake Street Keeps Their Hold Rating on Checkpoint Therapeutics (CKPT) - The Globe and Mail
Tower Research Capital LLC TRC Acquires 6,486 Shares of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates - GlobeNewswire
Checkpoint Therapeutics Secures $416M Merger Deal After Landmark FDA Cancer Drug Approval - Stock Titan
Envestnet Asset Management Inc. Has $214,000 Holdings in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Tecsys Placed as a Challenger in 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems - The Globe and Mail
Marshall Wace LLP Decreases Stake in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) - Defense World
Checkpoint Therapeutics (CKPT) Expected to Announce Earnings on Friday - Defense World
Microsoft’s Stock Rises 9% As Financial Results Top Estimates - The Globe and Mail
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc.CKPT - marketscreener.com
Checkpoint Therapeutics Inc Stock (CKPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.97%
1.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):